- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT00369512
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma (RAD0503)
A Phase II Trial of Erlotinib and Radiotherapy in Patients With Stage III Cutaneous Squamous Cell Carcinomas
Visão geral do estudo
Descrição detalhada
This is a single-institution, open-label, non-randomized phase II trial of erlotinib administered concomitantly with radiation therapy following surgical resection of gross disease. A total of 45 patients with previously unirradiated, high-risk cutaneous SCC requiring post-operative radiotherapy will be enrolled to assess the primary endpoints of time to recurrence and disease free survival. Pretreatment biopsies will be required to confirm the histological diagnosis of SCC. Four to six weeks after surgical resection, patients will begin erlotinib (150 mg po qd) beginning the first day of radiotherapy. Patients will receive 5040 cGy beginning on day 1 of therapy in standard fractionations. Patients will be followed to evaluate for toxicity based on NCI common toxicity criteria (v3.0). Patients will be followed on protocol for a minimum of 2 years with regularly scheduled CT scans, clinical evaluations, and laboratory work. Patients with residual or recurrent cancer will be taken off protocol for salvage therapy.
As a secondary objective, molecular response of tumors to erlotinib monotherapy will be determined. When possible, participants will be enrolled and treated for 14 days with erlotinib prior to surgical resection. The pretreatment biopsy specimen (control) will then be compared to tissue acquired during the surgical resection after 14 days of erlotinib (experimental group).
Tipo de estudo
Inscrição (Real)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35233
- University of Alabama at Birmingham Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Histologically proven primary or recurrent squamous cell carcinoma arising from the lip or skin of the face, ear, scalp or neck.
- Participants must meet one of the four criteria:
- 1. T4 cutaneous SCC as determined by physical exam, imaging studies, prior resections or biopsy. T4 disease is defined as tumor that invades deep extradermal structures such as cartilage, skeletal muscle (e.g., muscles of facial expression), parotid gland or bone.Patients with a T2 or greater squamous cell carcinoma of the lower lip who will require post operative radiation will be allowed.
- 2. Histologically proven regional lymph node involvement (N1 disease). Fine needle aspiration or biopsy can be used to demonstrate the presence of lymphatic spread.
- 3. Histologically proven parotid gland metastasis. Fine needle aspiration or biopsy can be used to demonstrate the presence of regional spread. Includes delayed regional metastasis; primary scalp or other skin lesion treated within 36 months that would drain into the involved parotid.
- 4. Patients who following surgical resection of the primary are found to have histologically positive lymph nodes (N1). Includes delayed regional metastasis; primary lip or cutaneous lesion treated within 36 months that would drain into the involved nodal basin.
- Age > 19 years
- Tumors must be considered surgically resectable.(Patients may be enrolled after surgery is completed as long as Erlotinib therapy and concurrent radiation is started within 8 weeks of surgical resection.)
- Required laboratory data obtained prior to beginning treatment: WBC > 1,500/ml; Platelets > 90,000; serum creatinine ≤ 2.0 mg/dl
- The patient may have had a prior non-cutaneous malignancy, but must be two years from treatment.
- Performance status of ≤ 2 (ECOG scale) and life expectancy ≥ 12 months.
- The patients must agree to use effective contraception if there is the potential for procreativity. Contraception must be conducted for at least 3 months following the study.
- Patients must sign informed consent
Exclusion Criteria:
- The patient has received prior radiation therapy to the head and neck.
- The patient is pregnant or lactating
- Patients with a prior history of head and neck mucosal cancers.
- Psychological condition that renders the patient unable to understand the informed consent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: N / D
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
---|---|
Experimental: Erlotinib
Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
|
Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
---|---|---|
Toxicities Associated With Combined Radiotherapy and Erlotinib Treatments.
Prazo: 2 years
|
Number of gradeable toxicities (via CTCAE manual) experienced by patients on this protocol--number of events
|
2 years
|
Median Time to Cancer Recurrence
Prazo: 2 years
|
Per protocol, patients were followed every 3 months for recurrent disease by physical exam and imaging (MRI/CT).
Recurrence, in most cases, is detected during routine history/physical exam.
If disease was detected during follow-up, every attempt was made to obtain pathological confirmation of recurrence.
|
2 years
|
Number of Patients With Recurrence at 2 Years
Prazo: 2 years
|
Rate of recurrence at 2 years.
|
2 years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Eben Rosenthal, M.D., University of Alabama at Birmingham
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- F060106002
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .
Ensaios clínicos em Câncer
-
Turku University HospitalLounais-Suomen SyöpäyhdistysAinda não está recrutandoSobrevivente de cancerFinlândia
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RetiradoSobrevivente de cancerEstados Unidos
-
University of Alabama at BirminghamNational Cancer Institute (NCI); Auburn UniversityConcluído
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)ConcluídoSobrevivente de cancerEstados Unidos, Guam
-
Wake Forest University Health SciencesNational Cancer Institute (NCI); National Institute of Mental Health (NIMH)ConcluídoSobrevivente de cancerEstados Unidos
-
Masonic Cancer Center, University of MinnesotaConcluídoSobrevivente de cancerEstados Unidos
-
Abramson Cancer Center of the University of PennsylvaniaConcluídoPlano de cuidados de sobrevivência LIVESTRONG: coleta contínua de dados e pesquisa de acompanhamentoPaciente com cancerEstados Unidos
-
University of New MexicoNew Mexico State University; University of New Mexico Cancer CenterConcluído
-
Ohio State University Comprehensive Cancer CenterConcluídoSobrevivente de cancerEstados Unidos
Ensaios clínicos em Erlotinib
-
China Medical University, ChinaGeneral Hospital of Shenyang Military Region; Shengjing Hospital; Liaoning Tumor... e outros colaboradoresDesconhecidoCâncer de Pulmão de Células Não Pequenas
-
Dartmouth-Hitchcock Medical CenterGenentech, Inc.; Ligand PharmaceuticalsConcluídoCarcinoma pulmonar de células não pequenasEstados Unidos
-
Samsung Medical CenterAstraZenecaDesconhecidoCâncer de Pulmão de Células Não Pequenas Positivo com Mutação EGFRRepublica da Coréia
-
Anhui Medical UniversityDesconhecidoAuto-eficácia | Toxicidade de MedicamentosChina
-
Peking University Third HospitalDesconhecidoCâncer de Pulmão de Células Não PequenasChina
-
Tian XieLinkDoc Technology (Beijing) Co. Ltd.RecrutamentoAdenocarcinoma | Carcinoma | Câncer de Pulmão de Células Não PequenasChina
-
Amsterdam UMC, location VUmcVitrOmics BVRescindidoTumores Sólidos Avançados | Metástase | InoperávelHolanda
-
Centro Nacional de Investigaciones Oncologicas...Apices Soluciones S.L.; Hospital Universitario de Fuenlabrada; Grupo Hospital...ConcluídoCarcinoma Pancreático AvançadoEspanha
-
Intergroupe Francophone de Cancerologie ThoraciqueConcluído